KT&G expands global tobacco and health footprints
The tobacco manufacturer maintains a consolidated network of 33 subsidiary companies.
The tobacco manufacturer KT&G operates a diverse business portfolio centered on cigarette production and sales. As of June 30, 2026, the company manages a consolidated group consisting of 33 subsidiaries, including one listed entity and 32 unlisted firms.
Cigarettes remain the primary revenue driver, accounting for 69.7% of total sales. The company is pursuing a trajectory of global expansion, highlighted by a 15-year long-term agreement with Philip Morris International to sell products in overseas markets excluding South Korea. To support this growth, the company has established entities in Kazakhstan and Turkey.
Beyond traditional tobacco, the company is diversifying into next-generation products and health supplements. It launched the lil AIBLE and Aiim electronic cigarette lines in 2022. In the health sector, its subsidiary Korea Ginseng Corp focuses on red ginseng products, which contributed 16.3% of consolidated sales. The company also maintains interests in pharmaceuticals through Youngjin Pharm and cosmetics via CosmoCos.
Research and development efforts are distributed across these sectors to secure future growth. The tobacco division is currently working on commercializing new categories and optimizing design quality for local markets. Meanwhile, the health functional food division is pursuing functional ingredient certifications from the Ministry of Food and Drug Safety.
Financial stability is supported by high credit ratings from domestic and international agencies. The company maintains AAA ratings from three domestic credit agencies and holds A- and A3 ratings from S&P and Moody's, respectively.
Legal and regulatory management remains a priority as the company handles various obligations. This includes a pending lawsuit regarding employee invention compensation with a scheduled judgment date of September 17, 2026.